Canlyniadau Chwilio - Tsen‐Fang Tsai

Mireinio'r Canlyniadau
  1. 1
    Updates on the Treatment of Erythrodermic Psoriasis

    Updates on the Treatment of Erythrodermic Psoriasis gan Yang Lo, Tsen‐Fang Tsai

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness

    Anti-interleukin and interleukin therapies for psoriasis: current evidence and clinical usefulness gan Ya‐Chu Tsai, Tsen‐Fang Tsai

    Cyhoeddwyd 2017
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    HLA-Cw1 and Psoriasis

    HLA-Cw1 and Psoriasis gan Yi‐Wei Huang, Tsen‐Fang Tsai

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center

    Exacerbation of Psoriasis Following COVID-19 Vaccination: Report From a Single Center gan Yi‐Wei Huang, Tsen‐Fang Tsai

    Cyhoeddwyd 2021
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes

    Overlapping Features of Psoriasis and Atopic Dermatitis: From Genetics to Immunopathogenesis to Phenotypes gan Ya‐Chu Tsai, Tsen‐Fang Tsai

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Topical egg yolk oil (4% cholesterol) and oral rosuvastatin for the treatment of disseminated superficial actinic porokeratosis

    Topical egg yolk oil (4% cholesterol) and oral rosuvastatin for the treatment of disseminated superficial actinic porokeratosis gan Chang‐Yu Hsieh, Tsen‐Fang Tsai

    Cyhoeddwyd 2025
    Cael y testun llawn
    Carta
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis

    Efficacy and Safety of Biologics and Small Molecules for Moderate-to-Severe Hidradenitis Suppurativa: A Systematic Review and Network Meta-Analysis gan Ya‐Chu Tsai, Chen‐Yiu Hung, Tsen‐Fang Tsai

    Cyhoeddwyd 2023
    Cael y testun llawn Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    How Cells Die in Psoriasis?

    How Cells Die in Psoriasis? gan Chung-Han Chen, Nan‐Lin Wu, Tsen‐Fang Tsai

    Cyhoeddwyd 2025
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Psoriasis and Co-morbidity

    Psoriasis and Co-morbidity gan Mina Amin, Erica B. Lee, Tsen‐Fang Tsai, Jashin J. Wu

    Cyhoeddwyd 2020
    Cael y testun llawn
    Revisão
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Use of anti‐tumor necrosis factor‐α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan

    Use of anti‐tumor necrosis factor‐α therapy in hepatitis B virus carriers with psoriasis or psoriatic arthritis: A case series in Taiwan gan Yung‐Tsu Cho, Chien‐Hung CHEN, Hsien‐Yi Chiu, Tsen‐Fang Tsai

    Cyhoeddwyd 2011
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C

    The safety profile of ustekinumab in the treatment of patients with psoriasis and concurrent hepatitis B or C gan Hsien‐Yi Chiu, Chi‐Hau Chen, Ming‐Shiou Wu, Y.‐P. Cheng, Tsen‐Fang Tsai

    Cyhoeddwyd 2013
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement

    Effectiveness and safety of secukinumab for psoriasis in real-world practice: analysis of subgroups stratified by prior biologic failure or reimbursement gan Tzong-Yun Ger, Yu‐Huei Huang, Rosaline Chung‐Yee Hui, Tsen‐Fang Tsai, Hsien‐Yi Chiu

    Cyhoeddwyd 2019
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp> trial

    Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp>... gan Richard Langley, Tsen‐Fang Tsai, Susan Flavin, Michael Song, B. Randazzo, Y. Wasfi, Jingzhi Jiang, S. Li, L. Puig

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  14. 14
    Psoriasis in Taiwan: From epidemiology to new treatments

    Psoriasis in Taiwan: From epidemiology to new treatments gan Hsien‐Yi Chiu, Ting‐Shun Wang, Po-Hua Chen, Shao-Hsuan Hsu, Ya‐Chu Tsai, Tsen‐Fang Tsai

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  15. 15
    Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2

    Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2 gan Mark C. Genovese, B. Combe, Joel M. Kremer, Tsen‐Fang Tsai, Frank Behrens, David H. Adams, Chin Lee, Lisa Kerr, Peter Nash

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  16. 16
    Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial gan Diamant Thaçi, Andrew Blauvelt, Kristian Reich, Tsen‐Fang Tsai, F. Vanaclocha, Külli Kingo, Michael Ziv, Andreas Pinter, Sophie Hugot, R. You, M. Milutinovic

    Cyhoeddwyd 2015
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  17. 17
    Inhibition of IL‐17A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis</i> infections

    Inhibition of IL‐17A by secukinumab shows no evidence of increased <i>Mycobacterium tuberculosis</i> infections gan Michael Kammüller, Tsen‐Fang Tsai, C.E.M. Griffiths, Nidhi Kapoor, Pappachan E. Kolattukudy, Dominique Brees, Salah‐Dine Chibout, Jorge Safi, Todd Fox

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  18. 18
    Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study

    Tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: long-term safety and efficacy in an open-label extension study gan Fernando Valenzuela, Neil J. Korman, Robert Bissonnette, Noémi Bakos, Tsen‐Fang Tsai, Melanie Harper, W.C. Ports, Huaming Tan, Anna M. Tallman, Hernán Valdez, Annie Gardner

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  19. 19
    Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study

    Safety Profile of Secukinumab in Treatment of Patients with Psoriasis and Concurrent Hepatitis B or C: A Multicentric Prospective Cohort Study gan Hsien‐Yi Chiu, Rosaline Chung‐Yee Hui, Yu-Huei Huang, Ruey-Yun Huang, Kai-Lung Chen, Ya‐Chu Tsai, Po-Ju Lai, Ting‐Shun Wang, Tsen‐Fang Tsai

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  20. 20
    Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis

    Design of Effisayil™ 2: A Randomized, Double-Blind, Placebo-Controlled Study of Spesolimab in Preventing Flares in Patients with Generalized Pustular Psoriasis gan Akimichi Morita, Siew Eng Choon, H. Bachelez, Milan J. Anadkat, Slaheddine Marrakchi, Min Zheng, Tsen‐Fang Tsai, H. Turki, Harry Hua, Sushmita Rajeswari, Christian Thoma, A. David Burden

    Cyhoeddwyd 2022
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: